Ophthalmic Drugs Market Size, Share & Forecast Report - 2026 to 2030

The global ophthalmic drugs market size is accounted for around USD 30 billion in 2019 and projected to grow at the CAGR of 5.9% market during the forecast period 2020-2027. Globally, the average life expectancy has been increasing and its posturing medical issues within the ophthalmology field are being strongly reflected. Among the elderly population, loss of eyesight is a major health problem. The growing prevalence of eye disorders has created a huge market for ophthalmic drugs. Moreover, new technologies combining drugs and device therapies are contributing significantly towards the development of the ophthalmic drugs market.

Market Insights:

The key factors responsible for the growth of the drug market are the aging population and the rising prevalence of ophthalmic disorders. In the base year 2019, prescription ophthalmic drugs are anticipated to hold the largest revenue share in the ophthalmic drugs market due to the increasing number of patients suffering from various new retinal disorders and complicated cases of glaucoma and cataract. Glaucoma ophthalmic drugs held the largest share in the therapeutic market segment due to a large patient pool suffering from ophthalmic disorders, early diagnosis, and treatment. The ophthalmic drugs market is currently dominated by North America due to the increasing prevalence of ophthalmic disorders, favorable reimbursement scenario, and developed healthcare infrastructure. The Asia Pacific will be the fastest-growing market due to the aging population, the large number of ophthalmic surgeries performed, and rapid development in the healthcare infrastructure.

Market Segment Insights:

The global ophthalmic drugs market is segmented by prescription types such as (prescription ophthalmic drugs, and over-the-counter drugs). The prescription ophthalmic drugs segment is anticipated to hold the largest market in the ophthalmic drugs market during the forecast period. The prime factor that would determine the growth of the prescription drugs segment includes the increasing number of patients suffering from various new retinal disorders and complicated cases of glaucoma and cataract. Moreover, the increasing rate of success for newly launched drugs which can only be bought by prescriptions would further assist the market growth. The therapeutic segment consists of (glaucoma ophthalmic drugs, retinal disorder ophthalmic drugs, dry eye ophthalmic drugs, and allergic conjunctivitis). Glaucoma ophthalmic drugs held the largest share in the global ophthalmic drugs market due to a large patient pool suffering from ophthalmic disorders, early diagnosis, and treatment.

Global Ophthalmic Drugs Market Segmentation:

By Prescription, 2018–2027 ($ Million)

• Prescription Ophthalmic Drugs
• Over-the-counter (OTC) Drugs

By Therapeutics, 2018–2027 ($ Million)

• Glaucoma Ophthalmic Drugs
• Retinal Disorder Ophthalmic Drugs
• Dry Eye Ophthalmic Drugs
• Allergic Conjunctivitis

By Geography, 2018-2027 ($ Million)

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Regional Insights:

North America, Latin America, Europe, Middle East and Africa, and Asia Pacific, markets together form the major regional markets for ophthalmic drug products. These regional markets are further sub-segmented into country-specific markets on the basis of demand and market growth of the ophthalmic drugs market. Among the considered regional markets, North America currently dominates the global ophthalmic drugs market, with the United States being the largest country-level market. The drivers for the North America market are a significant patient pool, early disease diagnosis and treatment, and favorable reimbursement policies. Additionally, Asia Pacific is anticipated to be the fastest-growing market for the geriatric population, rising investments in healthcare infrastructure and increasing prevalence of ocular diseases, which includes disorders of both the cornea and the retina.

Market Competition Assessment:

The major players currently operating in the global ophthalmic drugs market include Abbott healthcare, Allergan plc, Johnson and Johnson, Bayer, Novartis AG, Glaxosmithkline, Eyegate pharmaceuticals, LPath, Senten pharmaceuticals Co. Ltd., Cipla pharmaceuticals, Sun pharmaceutical industries, Ltd. and other notable players.

List of Key Companies:

• Abbott Healthcare
• Allergan Plc
• Akorn
• Bayer Johnson & Johnson
• Cipla Pharmaceuticals Bayer
• Eyemed
• Eyegate Pharmaceuticals
• Johnson & Johnson
• LPath
• Merck & Co.
• Novartis AG
• Pfizer, Inc.
• Senju Pharmaceutical Co., Ltd
• Senten Pharmaceutical Co. Ltd
• Sun Pharmaceutical Industries, Ltd.
• Valeant Pharmaceuticals, Inc.

Key Questions Answered by Ophthalmic Drugs Market Report

• Global ophthalmic drugs market forecasts from 2020-2027
• Regional ophthalmic drugs market forecasts from 2020-2027 covering Asia-Pacific, North America, Europe, Middle East and Africa, and Latin America
• Country level forecasts from 2020-2027 covering 15 major countries from the aforementioned regions
• Ophthalmic Drugs submarket forecasts from 2020-2027 covering the market by prescription, by therapeutics, and geography
• Various industry models such as SWOT analysis, Pestle Analysis, Porter’s Five Force model, Value Chain Analysis pertaining to ophthalmic drugs market
• Analysis of the key factors driving and restraining the growth of the global, regional, and country level ophthalmic drugs markets from 2020-2027
• Competitive Landscape and market positioning of top 10 players operating in the ophthalmic drugs market

Request a full report sample @ https://www.researchcorridor.com/request-sample/?id=27561